Patents by Inventor Christopher Seekamp

Christopher Seekamp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10588947
    Abstract: The invention provides a method for treating a subject who lacks endogenous sucrase activity by orally administering a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration of less than about 10 ng/ml.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 17, 2020
    Assignee: QOL Medical LLC
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Publication number: 20180193433
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Application
    Filed: December 15, 2017
    Publication date: July 12, 2018
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Patent number: 9849161
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: December 26, 2017
    Assignee: QOL Medical LLC
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Publication number: 20170000860
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Application
    Filed: September 20, 2016
    Publication date: January 5, 2017
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Patent number: 9469847
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: October 18, 2016
    Assignee: QOL Medical LLC
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Patent number: 9255261
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 9, 2016
    Assignee: QOL Medical LLC
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Publication number: 20150343032
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 3, 2015
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Publication number: 20150225707
    Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 13, 2015
    Applicant: QOL Medical LLC
    Inventors: Dayton T. Reardan, Christopher Seekamp
  • Patent number: 8466296
    Abstract: Processes and intermediates are provided for the preparation of substituted aminomethyl 2,3,8,9-tetrahydiO-7H-1,4-dioxino[2.3-e]indo]-8-ones of the Formula (A) wherein the variables n, R and R3 are as described herein. Such compounds are useful, for example, as dopamine receptor agonists.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: June 18, 2013
    Assignee: Ligand Pharmaceuticals
    Inventors: Zhe-qing Wang, Andrew Staab, Christopher Seekamp, George P. Luke